You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Harvard Business School
McKesson
Express Scripts

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 4,075,322

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,075,322
Title: Enzyme composition
Abstract:An enzyme of hydrolytic action, according to the invention, is a neutral protease having the molecular weight of about 37,000, the isoelectric point at pH 8.8, the optimum activity at 40.degree. - 45.degree. C, the stability range in aqueous solutions at pH 6.8 - 8.0, quickly inactivating in said solutions at temperatures above 50.degree. C. The enzymatic preparation containing the enzyme of hydrolytic action in an amount of 50 - 500 PU/g and the metabolites of the strains Streptomyces hygroscopicus. A method for preparing the hydrolytic enzyme, in which the strain Streptomyces hygroscopicus is cultivated on media containing assimilable sources of carbon and nitrogen, inorganic mineral salts, in deep aerobic conditions, with accumulation of the enzyme of hydrolytic action and the metabolites of the said strains in the culture fluid, followed by subsequent isolation of the enzyme. A medicinal preparation for treating respiratory diseases, purulent wounds and thermal burns, for treating and preventing empyema of the pleura, containing the enzyme of hydrolytic action in the quantity of 1 - 50 PU/mg, inactive protein and mineral salts.
Inventor(s): Bashkovich; Alexandr Pavlovich (Leningrad, SU), Zimnukhova; Evgenia Semenovna (Leningrad, SU), Prokopovich; Agnessa Vladimirovna (Leningrad, SU), Polatovskaya; Olga Grigorievna (Leningrad, SU), Pronina; Maria Ivanovna (Leningrad, SU), Kulbakh; Valter Osvaldovich (Leningrad, SU), Rivkina-Pevtsova; Khasya Ionovna (Leningrad, SU), Grinberg; Grigory Efimovich (Leningrad, SU)
Assignee:
Application Number:05/593,536
Patent Claims:see list of patent claims

Details for Patent 4,075,322

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial 1995-02-21 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial 1995-02-21 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Johnson and Johnson
McKesson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.